Business
Board Appointment
Board Appointment.
About this update from Nanoco Group Plc
[{"type":"text","content":"\n Evolutec Group PLC\n23 May 2006\n\n\nFor immediate release 23 May 2006\n\n\n\n\n\n EVOLUTEC GROUP PLC\n\n ('Evolutec' or 'the Company')\n\n\n\n Appointment of Non-Executive Director\n\n\n\nEvolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel\nproducts for the treatment of allergic, inflammatory and autoimmune diseases, is\npleased to announce the appointment of Malcolm Lawton Darvell as a Non-Executive\nDirector, effective from 24 May 2006.\n\n\n\nMr Darvell, aged 43, is currently the Chief Executive of Rontech Limited, a\nprivately held company that develops software for the global financial services\nindustry.\n\n\n\nMr Darvell has experience in both the financial and biotechnology sectors. He\nwas previously Chief Financial Officer of Tempest Consultants Limited, a company\ninvolved in equity market surveys, of Azur Environmental Limited, a company\nsupplying environmental monitoring equipment, and of Peptech Limited, the\nAustralian listed biotechnology company. Prior to that, Mr Darvell was Head of\nCorporate Finance Advisory at Nomura International and was instrumental in\nbuilding that franchise.\n\n\n\nThere are no further disclosures to be made in accordance with Schedule 2 (g) of\nthe AIM rules.\n\n\n\nDavid Bloxham, Evolutec's Chairman, said: 'I welcome Malcolm to Evolutec's\nBoard, where his financial knowledge and experience of growing smaller companies\nwill be of great value as Evolutec progresses to the next stage in the Company's\ndevelopment.'\n\n\n\n\n\n\n\nFor further information:\n\n\nEvolutec Group plc Tel: 0118 922 4480\nMark Carnegie Brown, Chief Executive Officer\nNicholas Badman, Chief Financial Officer\nwww.evolutec.co.uk\n\n\nBuchanan Communications Tel: 020 7466 5000\nMark Court/Mary-Jane Johnson/Catherine Breen\n\n\n\n\n\nNotes for Editors:\n\n\n\n\n\nAbout Evolutec Group plc\n\n\n\nEvolutec is a biopharmaceutical company developing drugs for allergy,\ninflammation and autoimmune disease.\n\n\n\nEvolutec's lead drug candidate, rEV131 has efficacy in both acute and chronic\nrespiratory indications including allergic rhinitis (hay fever) and asthma. In\n2005, Evolutec announced a positive result for rEV131 in a 112 patient Phase IIa\nproof of concept study in allergic rhinitis. rEV131 met the primary efficacy\nendpoint (p < 0.05). In addition, rEV131 showed efficacy agai...